title: Liver transaminase levels alone could not be the optimal method to estimate hepatic safety after statin administration in patients with chronic kidney disease.
authors: Christian
authors: C
authors: Molino
authors: Ruana
authors: R
authors: Tiseo
authors: Alfredo
authors: A
authors: De Giorgi
authors: Marco
authors: M
authors: Pala
authors: Roberto
authors: R
authors: Manfredini
mesh_terms: D015415:Biomarkers / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology; D008099:Liver / Q000187:drug effects*; D008107:Liver Diseases / Q000150:complications / Q000201:enzymology*; D000637:Transaminases / Q000097:blood*
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000637:Transaminases